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Prevalence of Penicillin-Resistant Streptococcus 
pneumoniae -- Connecticut, 1992-1993  
Streptococcus pneumoniae is an important cause of community-acquired bacterial pneumonia, meningitis, 
acute otitis media, and other infections (1). Infants, young children, and the elderly are most severely 
affected by pneumococcal disease (2). Although S. pneumoniae was once considered to be routinely 
susceptible to penicillin, since the mid-1980s the incidence of resistance of this organism to penicillin and 
other antimicrobial agents has been increasing in the United States (1-4). National surveillance for drug-
resistant S. pneumoniae (DRSP) is limited to testing invasive isolates from sentinel hospitals in 13 states. To 
determine the extent of antimicrobial susceptibility testing of S. pneumoniae and the prevalence of penicillin 
resistance among pneumococcal isolates from July 1992 through June 1993, in August 1993 the Connecticut 
Department of Public Health and Addiction Services (DPHAS) surveyed all 44 hospitals with clinical 
microbiology laboratories in Connecticut. This report summarizes the results of that survey.  
Hospital laboratories were asked whether pneumococcal isolates were tested for resistance to penicillin, 
which isolates were tested, which tests were used, the number of isolates tested from different body sites 
from July 1992 through June 1993, and the minimal inhibitory concentrations (MICs) for any resistant 
isolates. Forty-three (98%) of 44 hospital laboratories responded.  
Of the 43 hospital laboratories, 33 reported performing antimicrobial susceptibility tests on pneumococcal 
isolates, nine sent pneumococcal isolates to other laboratories for testing, and one neither performed such 
tests on pneumococcal isolates nor sent isolates to other laboratories for testing.  
In 15 of the 33 laboratories, penicillin susceptibility testing was limited to qualitative disk diffusion (using 
an oxacillin disk). Nine laboratories screened pneumococcal isolates by disk diffusion, then confirmed 
penicillin resistance by determination of a quantitative MIC. Nine laboratories determined the penicillin 
MIC for all pneumococcal isolates.  
MIC data were provided by 14 of the 18 laboratories that performed such tests for pneumococcal isolates. 
MICs were reported for 846 isolates collected during July 1992-June 1993. Penicillin resistance was defined 
as MIC greater than or equal to 0.1 ug/mL, and high-level resistance was defined as MIC greater than or 
equal to 2.0 ug/mL (5). Penicillin-resistant isolates were reported from four of 14 hospitals. Eighteen 
isolates (2.1%) from any body site were penicillin resistant, including five (1.3%) of 400 isolates from 
usually sterile sites. Overall, three isolates (one each from blood, sputum, and nasal fluid) were highly 
resistant. Two of these isolates had penicillin MICs greater than or equal to 4.0 ug/mL.  
Reported by: EH Simpson, ML Cartter, MD, JL Hadler, MD, State Epidemiologist, Connecticut Dept of 
Public Health and Addiction Svcs. Child and Adult Immunization Br, National Immunization Program; 
Nosocomial Pathogens and Laboratories Br, Hospital Infections Program, Childhood and Respiratory 
Diseases Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, CDC.  
Editorial Note 
Editorial Note: The spread of DRSP strains may increase the public health impact of S. pneumoniae 
infections because of increased morbidity and reductions in the effectiveness of antimicrobial treatment for 
pneumococcal disease. Of special concern is resistance to extended-spectrum cephalosporins, which are 
often used as empiric therapy for meningitis (3).  
During 1979-1987, only one (0.02%) of 4585 pneumococcal sterile-site isolates submitted to CDC's sentinel 
hospital surveillance system were highly resistant to penicillin; in comparison, during 1992, seven (1.3%) of 
544 such isolates were highly resistant (4,6). In some pediatric populations, up to 30% of pneumococcal 
isolates are penicillin resistant at some level, with a substantial proportion of strains resistant to multiple 
drugs (3). Although information regarding resistance to other antimicrobial drugs was unavailable in the 
Connecticut survey, the overall prevalence of penicillin-resistant strains in Connecticut was low through 
June 1993. However, resistant pneumococcal strains can spread rapidly in communities (7,8), and DPHAS 
is conducting surveillance for antimicrobial resistance.  
Because penicillin susceptibility cannot be assumed, pneumococcal isolates associated with disease should 
be screened routinely for penicillin resistance by disk diffusion using a 1-ug oxacillin disk (9), which is 
highly sensitive -- although not 100% specific -- for penicillin resistance. Screening cannot reliably quantify 
the degree of penicillin resistance; therefore, pneumococcal isolates with oxacillin zone sizes less than or 
equal to 19 mm should be further tested by determination of MICs for penicillin (9), as well as for other 
drugs likely to be used in treatment. Some pneumococci with either intermediate or high-level penicillin 
resistance also may be resistant to extended-spectrum cephalosporins; therefore, penicillin-resistant isolates 
should be tested by MIC for susceptibility to either ceftriaxone or cefotaxime (3,5).  
To optimize empiric regimens and initial therapy for pneumococcal infections, clinical health-care providers 
must be informed about the prevalence and patterns of drug resistance among isolates in their communities. 
Statewide surveillance for DRSP as a notifiable condition has been initiated in Colorado, Connecticut, and 
New Jersey. CDC, in collaboration with the Council of State and Territorial Epidemiologists and the 
Association of State and Territorial Public Health Laboratory Directors, is developing strategies for 
collecting information on pneumococcal drug resistance in other states and for preventing morbidity and 
death associated with infection with resistant strains (3). Because antimicrobial susceptibility testing should 
be conducted routinely on invasive pneumococcal isolates, emphasis must be placed on developing methods 
to compile and analyze results, alerting health-care providers in communities in which resistant 
pneumococcal strains are prevalent, and identifying areas requiring more intensive epidemiologic 
assessment.  
In areas where pneumococci resistant to extended-spectrum cephalosporins are prevalent, empiric therapy 
with vancomycin and an extended-spectrum cephalosporin should be considered for cases of life-
threatening infection (e.g., meningitis) potentially caused by S. pneumoniae until results of culture and 
susceptibility testing are known. The emergence of drug-resistant pneumococcal infections underscores the 
need for adherence to recommendations of the Advisory Committee on Immunization Practices that persons 
aged greater than or equal to 2 years with medical conditions placing them at increased risk for serious 
pneumococcal infection and all persons aged greater than or equal to 65 years should receive 23-valent 
pneumococcal capsular polysaccharide vaccine (10); no pneumococcal vaccine is licensed for children aged 
less than 2 years.  
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